CureVac and Fareva Sign Agreement For Fill & Finish Manufacturing of Curevac's COVID-19 Vaccine Candidate, CVnCoV TÜBINGEN, Germany/ BOSTON, USA and Luxembourg

CureVac and Fareva Sign Agreement For Fill & Finish

Manufacturing of Curevac's COVID-19 Vaccine Candidate, CVnCoV

T BINGEN, Germany/ BOSTON, USA and Luxembourg -

December 9, 2020 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class

of transformative medicines based on messenger ribonucleic acid (mRNA), and Fareva today announced an agreement regarding the fill

& finish manufacturing of CureVac s COVID-19 vaccine candidate, CVnCoV, at Fareva's Pau and Val-de-Reuil-sites

"We are proud to contribute to the manufacturing of this

innovative vaccine candidate from CureVac. This agreement confirms Fareva's strategy of investing significantly in the areas

of sterile manufacturing, enlarging our technology offering," said Alexandre Bastit, Vice President of EMEA Pharma Sales

"We are pleased to partner with Fareva for the fill &

finish manufacturing of our COVID-19 vaccine candidate in France," added Dr. Florian von der M lbe, Chief Production

Officer of CureVac. "Fareva is an experienced and reliable partner that will help to increase the overall production capacity

for our vaccine, and by partly manufacturing our vaccine in France, we will hopefully be in a position to contribute to the protection

of French citizens against the virus."

CureVac is building an integrated European vaccine manufacturing

network with several Contract Development and Manufacturing Organization (CDMO) partners. With this strategy, the company will

significantly increase CureVac's existing manufacturing capacity, allowing CureVac to develop up to several hundred million

doses of its vaccines per year and to manage potential supply chain risks by working with partners during each of the key steps

in the manufacturing process.

Thanks to the agreement announced today, Fareva will provide

the production capacity for filling vials with the vaccine and the eluent at its sites in Pau and Val-de-Reuil, France, supporting

the production of millions of doses of CureVac's COVID-19 vaccine candidate. The mRNA vaccine will be supplied to Fareva

by CureVac. Fareva's Val-de-Reuil-site accounts for more than 500 employees and is dedicated to the manufacturing of sterile

Active Pharmaceutical Ingredients (APIs) and sterile finished dosage forms (e.g., lyophilized vials, prefilled syringes and ampoules).

Over the last 10 years, Fareva has invested over 80 million euros in this site and created 250 jobs. The site in Pau is a more

recent acquisition by Fareva from Pierre Fabre Group, and is supported by more than 250 employees. It is dedicated to the sterile

fill & finish manufacturing of biologics and high potent APIs, including freeze-dried products.

CureVac began development

of its mRNA-based COVID-19 vaccine candidate in January 2020. The compound is an optimized, non-chemically modified mRNA, encoding

the pre-fusion stabilized full-length spike protein of the SARS-CoV-2 virus. Phase 1 and 2a clinical trials of CVnCoV began in

June and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated

across all tested doses and induced strong antibody responses in addition to first indication of T cell activation. The quality

of immune response was comparable to recovered COVID-19 patients, mimicking the immune response after natural COVID-19 infection.

The data support CureVac's decision to advance a 12 g dose in its upcoming pivotal Phase 2b/3 study, which CureVac

plans to initiate before the end of 2020. Clinical trial material is provided by the company's substantial production capacities

for mRNA vaccines at its headquarters in T bingen, supported by the current expansion of manufacturing capacities to allow

for broad-scale manufacturing of CVnCoV for potential commercial supply preparedness.

CureVac is a global clinical-stage

biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and

optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use

of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a

broad range of diseases. Based on its proprietary technology, the company has built a deep clinical pipeline across the areas of

prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public

offering on the New York Nasdaq in August 2020. It is headquartered in T bingen, Germany, and employs more than 500 people

at its sites in T bingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.

Fareva, a family-owned company whose

strength lies in its financial independence, is one of the world's leading CDMOs in the pharmaceuticals, cosmetics, make-up,

and industrial and homecare fields. Fareva operates in 11 countries with 39 factories and has more than 12,000 employees with annual

revenue reaching 1.8 billion in 2019. For further information, please come and visit us at www.fareva.com.

CureVac Media Contact

Vice President Communications

T: +49 7071 9883-1577

CureVac Investor Relations

Dr. Sarah Fakih, Vice President

CureVac, T bingen, Germany

T: +49 7071 9883-1298

M: +49 160 90 496949

Media Contact Fareva

Sebastien Poncet, Vice President Strategic Licensing

Marie Wicart, Communication Director

Forward-Looking Statements

This press release contains statements that constitute "forward

looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including

statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the "company")

regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion

of the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such

forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate,"

"plan," "seek," "project," or "expect," "may," "will,"

"would," "could," "potential," "intend," or "should," the negative

of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions

and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's

performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks,

uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility

in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical

trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability

to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations

and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects

of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel,

reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due

to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers

are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and

could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included

in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation

to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events

or developments, except as required by law.

For further information,

please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC).

You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.